Despite Headwinds US IPOs Show Few Signs Of Slowing In Q3

Fifteen drug development firms raised $1.4bn via initial public offerings in the US during the third quarter, which is equal to the quarterly average during the first half of the year and shows that despite recent biotechnology stock headwinds IPOs have not slowed – at least, not yet.